Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U06 Substudy 06B in previously PD-1/PD-L1–treated esophageal squamous cell carcinoma
jRCT2031220582Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 2, open-label trial of pembrolizumab, mk-4830, sacituzumab tirumotecan, paclitaxel, irinotecan and 1 more in Esophageal Squamous Cell Carcinoma (ESCC) (5 arms), sponsored by Merck & Co. Primary endpoints: Number of participants with dose-limiting toxicity (DLT) during safety lead-in, Number of participants experiencing adverse events (AEs) during safety lead-in and 2 more. Started Jul 2023; status: recruiting.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on jRCT2031220582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220582.